Cervical cancers are the fourth most common and most deadly cancer in women worldwide. Despite being a tremendous public health burden, few novel approaches to improve care for these malignancies have been introduced. We discuss the potential for proliferating cell nuclear antigen (PCNA) inhibition to address this need as well as the advantages and disadvantages for compounds that can therapeutically inhibit PCNA with a specific focus on cervical cancer.
Keywords: chemotherapy; disease control; human papillomavirus; oncogenesis; virus classification.
© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.